alexa Noonan syndrome | Switzerland| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Relevant Topics

Noonan Syndrome

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Noonan syndrome

    Noonan syndrome is a condition that is characterized by mildly unusual facial characteristics, short stature, heart defects, bleeding problems, skeletal malformations, and many other signs and symptoms. 15 studies were conducted in which growth hormone (GH) therapy was used in children with Noonan syndrome. Data show consistent increases in mean height standard deviation score (SDS), with first-year changes of up to 1.26 SDS. Among studies reporting adult or near-adult height, GH therapy over 5-7 years resulted in adult height SDS from -0.6 to -2.1, with up to 60% of subjects in some studies achieving adult height within 1 SDS of mid-parental height.

  • Noonan syndrome

    There is currently no single treatment for Noonan syndrome, but it's often possible to successfully manage many aspects of the disorder. Severe heart defects may need to be repaired with surgery, and growth hormone medication may be used to help prevent restricted growth. Recurrence risk for parents who do not appear to be affected or who have only some facial features of Noonan syndrome is 5%. Gonadal mosaicism may account for this increase over population risk. Affected individuals have a 50% chance of passing on the disorder with each pregnancy. Alterations in four genes - PTPN11, SOS1, RAF1 and KRAS - have been identified to date.

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings